Loading…
Reported covered position: CHIEF OF STAFF, SEN. THOMAS CARPER
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Biosimilars Access and Affordability Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VERTEX PHARMACEUTICALS via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to coverage of opioid alternatives.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| VERTEX PHARMACEUTICALS |
| 65 |
| 2011–2026 |
| TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) | 60 | 2012–2026 |
| ENVIRONMENTAL DEFENSE ACTION FUND | 59 | 2012–2026 |
| ASTELLAS PHARMA US, INC. | 58 | 2009–2026 |
| FWD.US | 57 | 2013–2026 |
| AMERICAN PROPERTY CASUALTY INSURANCE ASSOCIATION | 51 | 2007–2020 |
| MERCK & CO., INC. | 49 | 2014–2026 |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 44 | 2013–2023 |
| HARLEY-DAVIDSON FINANCIAL SERVICES, INC. | 44 | 2009–2020 |
| TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF GENENTECH, INC. | 43 | 2011–2026 |
| EMD SERONO, INC. | 41 | 2016–2026 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 39 | 2009–2025 |
| JOHNSON CONTROLS INTERNATIONAL PLC (FKA TYCO INTERNATIONAL MANAGEMENT COMPANY) | 36 | 2009–2019 |
| BUSINESS ROUNDTABLE | 31 | 2007–2019 |
| UNITED SERVICES AUTOMOBILE ASSOCIATION | 31 | 2006–2014 |
| NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS (FKA NAHU) | 28 | 2015–2021 |
| TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF ELI LILLY AND COMPANY | 28 | 2020–2026 |
| MASTERCARD | 27 | 2007–2023 |
| THE BUSINESS ROUNDTABLE | 27 | 2019–2025 |
| BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) | 26 | 2020–2025 |
| EOS ENERGY ENTERPRISES LLC (FKA EOS ENERGY STORAGE LLC) | 25 | 2020–2026 |
| JOHNSON CONTROLS INC | 25 | 2019–2024 |
| ACADIA PHARMACEUTICALS INC | 24 | 2020–2026 |
| INCYTE CORPORATION | 24 | 2020–2026 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 23 | 2021–2026 |
| BLOOM ENERGY | 20 | 2023–2026 |
| NEW YORK LIFE INSURANCE COMPANY | 18 | 2010–2014 |
| THE ALLSTATE CORPORATION | 18 | 2015–2018 |
| DEUTSCHE BANK USA (FKA DEUTSCHE BANK SECURITIES INC.) | 17 | 2009–2013 |
| Alnylam Pharmaceuticals, Inc. | 16 | 2023–2026 |
| GILEAD SCIENCES, INC. | 16 | 2023–2026 |
| WHIRLPOOL CORPORATION | 16 | 2012–2015 |
| BAY BRIDGE STRATEGIES INC (ON BEHALF OF LUMERIS INC ) | 15 | 2009–2012 |
| JULIAN ROBERTSON | 15 | 2008–2012 |
| NEW CASTLE COUNTY DELAWARE | 15 | 2007–2010 |
| UNUM GROUP | 15 | 2011–2014 |
| AMERICAN HOTEL & LODGING ASSOCIATION | 14 | 2016–2018 |
| AMERICAN INSTITUTE OF CERTIFIED PUBLIC ACCOUNTANTS | 14 | 2008–2011 |
| GRID UNITED LLC | 14 | 2023–2026 |
| LEON MEDICAL CENTER | 14 | 2009–2012 |
| SUNPOWER CORPORATION | 14 | 2020–2023 |
| ABBVIE, INC. | 13 | 2013–2026 |
| ALLIANCE FOR QUALITY NURSING HOME CARE | 13 | 2009–2012 |
| CARBON REMOVAL ALLIANCE | 13 | 2023–2026 |
| CHUBB INA HOLDINGS INC | 13 | 2007–2016 |
| CUBA DEMOCRACY PUBLIC ADVOCACY, CORP. | 13 | 2013–2016 |
| QUIDNET ENERGY INC. | 13 | 2022–2025 |
| EQUIPMENT LEASING AND FINANCE ASSOCIATION | 12 | 2017–2023 |
| FINSECA | 12 | 2023–2026 |
| BAY BRIDGE STRATEGIES (ON BEHALF OF BLOOM ENERGY) | 11 | 2016–2020 |
| PRIVATE EQUITY COUNCIL | 11 | 2007–2009 |
| BIOSCRIP | 10 | 2017–2019 |
| CELGENE CORPORATION | 10 | 2018–2019 |
| ENERGY STORAGE ITC COALITION | 10 | 2021–2022 |
| MATTEL INC | 10 | 2007–2009 |
| MICROSOFT CORPORATION | 10 | 2007–2016 |
| ROIVANT SCIENCES, INC. | 10 | 2018–2020 |
| THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY | 10 | 2024–2026 |
| COALITION FOR THE AMERICAN DREAM | 9 | 2019–2020 |
| HAUCK STRATEGIES LLC (OBO CONSUMERS AND REFINERS UNITED FOR DOMESTIC ENERGY) | 9 | 2014–2015 |
| HAUCK STRATEGIES, LLC (OBO HOLLYFRONTIER CORPORATION) | 9 | 2014–2015 |
| NUSANO, INC. | 9 | 2023–2025 |
| BAY BRIDGE STRATEGIES (ON BEHALF OF PLUG POWER) | 8 | 2016–2018 |
| BRISTOL MYERS SQUIBB | 8 | 2020–2021 |
| DEFENDING DEMOCRACY TOGETHER | 8 | 2021–2024 |
| EVERGLADES PROTECTION ALLIANCE, INC. | 8 | 2021–2022 |
| GEORGIALINK PUBLIC AFFAIRS GROUP, LLC (O.B.O. DOUGHERTY COUNTY, GA) | 8 | 2025–2026 |
| PMI GLOBAL SERVICES INC. | 8 | 2013–2014 |
| WE WORK FOR HEALTH | 8 | 2021–2023 |
| WILMER HALE (ON BEHALF OF NISOURCE INC.) | 8 | 2019–2020 |
| CASE NEW HOLLAND INDUSTRIAL INC. | 7 | 2013–2021 |
| LABWARE, INC. | 7 | 2020–2021 |
| THE ICKES AND ENRIGHT GROUP (ON BEHALF OF NUCLEAR DEVELOPMENT, LLC) | 7 | 2016–2017 |
| WEX INC. | 7 | 2023–2025 |
| ALTRIA CLIENT SERVICES INC | 6 | 2007–2008 |
| COMMUNITIES AGAINST REGIONAL INTERCONNECT | 6 | 2007–2008 |
| ELECTRONIC PAYMENTS COALITION ("EPC") | 6 | 2007–2008 |
| ENVIRONMENTAL DEFENSE FUND | 6 | 2008–2013 |
| HEALTHSPRING, INC. | 6 | 2011–2012 |
| HONEYWELL INTERNATIONAL | 6 | 2021–2022 |
| MAYER BROWN ROWE AND MAW | 6 | 2007–2008 |
| QUALCOMM INC | 6 | 2021–2022 |
| SANTANDER CONSUMER USA | 6 | 2014–2015 |
| FANNIE MAE | 5 | 2007–2008 |
| MERRILL LYNCH | 5 | 2008 |
| PROJECT FOR OPPORTUNITY AND SAFETY, INC. | 5 | 2016 |
| TELECOMMUNICATIONS INDUSTRY ASSOCIATION | 5 | 2014 |
| THOMA BRAVO, L.P. | 5 | 2024–2025 |
| U.S.-RUSSIA BUSINESS COUNCIL | 5 | 2012 |
| UNION PACIFIC RAILROAD COMPANY | 5 | 2021 |
| BAY BRIDGE STRATEGIES (ON BEHALF OF KLEINER PERKINS CAUFIELD & BYERS) | 4 | 2012 |
| DEMOCRATIC MAJORITY FOR ISRAEL | 4 | 2026 |
| HUMANITY FORWARD | 4 | 2022 |
| KLEINER PERKINS CAUFIELD & BYERS | 4 | 2011–2012 |
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Richard L. Trumka Protecting the Right to Organize Act of 2025
Client: FINSECA · Firm: TIBER CREEK GROUP
Issues related to H.R. 20/S. 852 - Richard L. Trumka Protecting the Right to Organize Act of 2025.
Richard L. Trumka Protecting the Right to Organize Act of 2025
Client: FINSECA · Firm: TIBER CREEK GROUP
Issues related to H.R. 20/S. 852 - Richard L. Trumka Protecting the Right to Organize Act of 2025.
Richard L. Trumka Protecting the Right to Organize Act of 2025
Client: FINSECA · Firm: TIBER CREEK GROUP
Issues related to H.R. 20/S. 852 - Richard L. Trumka Protecting the Right to Organize Act of 2025.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: ABBVIE INC. · Firm: TIBER CREEK GROUP
Issues related to reimbursement of medications under Medicare Part B, including H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: ABBVIE INC. · Firm: TIBER CREEK GROUP
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Protecting Patient Access to Cancer and Complex Therapies Act
Client: ABBVIE INC. · Firm: TIBER CREEK GROUP
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to H.R. 8013 - Keep Innovators in America Act; Issues related to H.R. 7147 - Further Additional Continuing Appropriations Act, 2026; Issues related to Temporary Protected Status (TPS).
General immigration issues; Issues related to the Secure America Act (P.L. 119-98); Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
SAFE Drugs Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
SAFE Drugs Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD).
SAFE Drugs Act of 2025
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Homeland Security and Further Additional Continuing Appropriations Act, 2026.
Client: FWD.US · Firm: TIBER CREEK GROUP
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to H.R. 8013 - Keep Innovators in America Act; Issues related to H.R. 7147 - Further Additional Continuing Appropriations Act, 2026; Issues related to Temporary Protected Status (TPS).
Farm, Food, and National Security Act of 2026
Client: NATIONAL GOVERNORS ASSOCIATION · Firm: TIBER CREEK GROUP
Issues related to SNAP in H.R. 7567 - Farm, Food, and National Security Act of 2026 and in discussion draft, the Agricultural Act of 2026 (Farm Bill 2.0).
Farm, Food, and National Security Act of 2026
Client: NATIONAL GOVERNORS ASSOCIATION · Firm: TIBER CREEK GROUP
Issues related to SNAP in H.R. 7567 - Farm, Food, and National Security Act of 2026; Issues related to SNAP in S. 5526 - Agricultural Act of 2026.
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to H.R. 8013 - Keep Innovators in America Act; Issues related to H.R. 7147 - Further Additional Continuing Appropriations Act, 2026; Issues related to Temporary Protected Status (TPS).
Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act
Client: THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY · Firm: TIBER CREEK GROUP
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act
Client: THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY · Firm: TIBER CREEK GROUP
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
SECURE Data Act
Client: THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY · Firm: TIBER CREEK GROUP
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
SECURE Data Act
Client: THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY · Firm: TIBER CREEK GROUP
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Making appropriations for national security, Department of State, and related programs for the fiscal year ending September 30, 2027, and for other purposes.
Client: DEMOCRATIC MAJORITY FOR ISRAEL · Firm: TIBER CREEK GROUP
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027; Issues related to S.Res.852 - A resolution requesting information on Israel's human rights practices pursuant to section 502B(c) of the Foreign Assistance Act of 1961.
Making appropriations for national security, Department of State, and related programs for the fiscal year ending September 30, 2027, and for other purposes.
Client: DEMOCRATIC MAJORITY FOR ISRAEL · Firm: TIBER CREEK GROUP
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027.
Better Energy Storage and Safety Act
Client: EOS ENERGY ENTERPRISES LLC (FKA EOS ENERGY STORAGE LLC) · Firm: TIBER CREEK GROUP
Issues related to energy storage; Issues related to H.R. 8706 - Better Energy Storage and Safety Act; Issues related to domestic content and advanced manufacturing; Issues related to fire safety.
Better Energy Storage and Safety Act
Client: EOS ENERGY ENTERPRISES LLC (FKA EOS ENERGY STORAGE LLC) · Firm: TIBER CREEK GROUP
Issues related to energy storage; Issues related to H.R. 8706 - Better Energy Storage and Safety Act; Issues related to domestic content and advanced manufacturing; Issues related to fire safety.
National Defense Authorization Act for Fiscal Year 2027
Client: ENTERGY SERVICES LLC · Firm: TIBER CREEK GROUP
Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027.
National Defense Authorization Act for Fiscal Year 2027
Client: DEMOCRATIC MAJORITY FOR ISRAEL · Firm: TIBER CREEK GROUP
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027; Issues related to S.Res.852 - A resolution requesting information on Israel's human rights practices pursuant to section 502B(c) of the Foreign Assistance Act of 1961.
National Defense Authorization Act for Fiscal Year 2027
Client: ENTERGY SERVICES LLC · Firm: TIBER CREEK GROUP
Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027.
National Defense Authorization Act for Fiscal Year 2027
Client: DEMOCRATIC MAJORITY FOR ISRAEL · Firm: TIBER CREEK GROUP
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to intellectual property protections; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Issues related to intellectual property protections; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
ASAP Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to S. 3267 - ASAP Act.
General immigration issues; Issues related to the Secure America Act (P.L. 119-98); Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to H.R. 8013 - Keep Innovators in America Act; Issues related to H.R. 7147 - Further Additional Continuing Appropriations Act, 2026; Issues related to Temporary Protected Status (TPS).
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
SAFE Drugs Act of 2026
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) · Firm: TIBER CREEK GROUP
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Issues related to SNAP in H.R. 7567 - Farm, Food, and National Security Act of 2026; Issues related to SNAP in S. 5526 - Agricultural Act of 2026.
Richard L. Trumka Protecting the Right to Organize Act of 2025
Client: FINSECA · Firm: TIBER CREEK GROUP
Issues related to H.R. 20/S. 852 - Richard L. Trumka Protecting the Right to Organize Act of 2025.
Richard L. Trumka Protecting the Right to Organize Act of 2025
Client: FINSECA · Firm: TIBER CREEK GROUP
Issues related to H.R. 20/S. 852 - Richard L. Trumka Protecting the Right to Organize Act of 2025.
Richard L. Trumka Protecting the Right to Organize Act of 2025
Client: FINSECA · Firm: TIBER CREEK GROUP
Issues related to H.R. 20/S. 852 - Richard L. Trumka Protecting the Right to Organize Act of 2025.
Chinese Military and Surveillance Company Sanctions Act of 2024
Client: AMGEN INC · Firm: TIBER CREEK GROUP
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Chinese Military and Surveillance Company Sanctions Act of 2024
Client: MERCK & CO., INC · Firm: TIBER CREEK GROUP
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ARCXIS · Firm: TIBER CREEK GROUP
Issues related to H.R.1 - One Big Beautiful Bill Act.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
Mikaela Naylon Give Kids a Chance Act
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act. Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21).
Mikaela Naylon Give Kids a Chance Act
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act; Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing reforms.
Mikaela Naylon Give Kids a Chance Act
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act; Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing reforms.
Mikaela Naylon Give Kids a Chance Act
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R.1672 - Maintaining Investments in New Innovation Act.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to home infusion under Medicare FFS; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R.1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S.1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
2026 · third_quarter · Q3
Issues related to the Medicare Advantage and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to S. 3267 - ASAP Act.
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509/S. 3794 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to H.R. 20/S. 852 - Richard L. Trumka Protecting the Right to Organize Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to drug pricing; Issues related to the Inflation Reduction Act (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to reimbursement of medications under Medicare Part B, including H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENTERGY SERVICES LLC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to the Clean Air Act.
Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027.
Issues related to federal permitting reform; Issues related to electricity transmission; Issues related to the implementation of the ADVANCE Act (PL 118-67); Issues related to NRC nominations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to tariff policy and supply chain policy.
GRID UNITED LLC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to electricity transmission and permitting reform.
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEMOCRATIC MAJORITY FOR ISRAEL via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027; Issues related to S.Res.852 - A resolution requesting information on Israel's human rights practices pursuant to section 502B(c) of the Foreign Assistance Act of 1961.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF GENENTECH, INC.) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare Part B Pricing Reform; Issues relating to Medicaid Pricing Reform.
Issues related to the 340B Program - Public Health Service Act (PL 78-410).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Issues related to intellectual property protections; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to intellectual property protections.
Issues related to immunization policy.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to Health and Human Services Center for Medicare and Medicaid Innovation GUARD Demo; Issues related to Medicare coverage of Vitilligo.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to reproductive healthcare and IVF.
Issues related to Medicare Part D and Part B Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of USC 48(c)(1)(E) - Qualified fuel cell property.
Issues related to the deployment of fuel cells, electrolyzers, hydrogen, and carbon capture; Issues related to onsite power generation and grid stability; Issues related to permitting reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform.
Issues related to the 340B Program - Public Health Service Act (PL 78-410).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EOS ENERGY ENTERPRISES LLC (FKA EOS ENERGY STORAGE LLC) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to energy storage; Issues related to H.R. 8706 - Better Energy Storage and Safety Act; Issues related to domestic content and advanced manufacturing; Issues related to fire safety.
Issues related to installation readiness.
Filing targets: Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office
ENVIRONMENTAL DEFENSE ACTION FUND via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to climate change and carbon pricing; Issues related to environmental regulations.
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
SECRETARY OF STATE, STATE OF DELAWARE via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to corporate governance; Issues related to port funding.
Issues related to the implementation of the Infrastructure Investment and Jobs Act (PL 117-58); Issues related to the PIDP grant process; Issues related to port funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL GOVERNORS ASSOCIATION via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to SNAP in H.R. 7567 - Farm, Food, and National Security Act of 2026; Issues related to SNAP in S. 5526 - Agricultural Act of 2026.
Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to permitting reform; Issues related to S.5653 - Bipartisan American Affordability and Jobs Act of 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Issues related to insurance regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GEORGIALINK PUBLIC AFFAIRS GROUP, LLC (O.B.O. DOUGHERTY COUNTY, GA) via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to general appropriations; Issues related to federal grant opportunities; General state and local issues.
Issues related to general appropriations; Issues related to federal grant opportunities; General state and local issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2026 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBVIE INC. via TIBER CREEK GROUP
2026 · third_quarter · RA
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
DEFINIUM THERAPEUTICS via TIBER CREEK GROUP
2026 · third_quarter · RR
Issues related to FDA approved Psychedelics; Issues related to DEA rescheduling of FDA approved products.
Issues related to FDA approved Psychedelics; Issues related to DEA rescheduling of FDA approved products.
THEA ENERGY via TIBER CREEK GROUP
2026 · third_quarter · RR
Issues related to fusion power.
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to drug pricing; Issues related to the Inflation Reduction Act (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EOS ENERGY ENTERPRISES LLC (FKA EOS ENERGY STORAGE LLC) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to installation readiness.
Issues related to energy storage; Issues related to H.R. 8706 - Better Energy Storage and Safety Act; Issues related to domestic content and advanced manufacturing; Issues related to fire safety.
Filing targets: Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office
2026 · second_quarter · Q2
Issues related to H.R. 20/S. 852 - Richard L. Trumka Protecting the Right to Organize Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENTERGY SERVICES LLC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to federal permitting reform; Issues related to electricity transmission; Issues related to the implementation of the ADVANCE Act (PL 118-67); Issues related to NRC nominations.
Issues related to the Clean Air Act.
Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the Medicare Advantage and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF GENENTECH, INC.) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to Medicare Part B Pricing Reform; Issues relating to Medicaid Pricing Reform.
Issues related to the 340B Program - Public Health Service Act (PL 78-410).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Issues related to intellectual property protections; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026.
Issues related to immunization policy.
Issues related to intellectual property protections.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to Health and Human Services Center for Medicare and Medicaid Innovation GUARD Demo.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to reproductive healthcare and IVF.
Issues related to Medicare Part D and Part B Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the deployment of fuel cells, electrolyzers, hydrogen, and carbon capture; Issues related to onsite power generation and grid stability.
Issues related to implementation of USC 48(c)(1)(E) - Qualified fuel cell property.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the 340B Program - Public Health Service Act (PL 78-410).
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GEORGIALINK PUBLIC AFFAIRS GROUP, LLC (O.B.O. DOUGHERTY COUNTY, GA) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to general appropriations; Issues related to federal grant opportunities; General state and local issues.
Issues related to general appropriations; Issues related to federal grant opportunities; General state and local issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL GOVERNORS ASSOCIATION via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to SNAP in H.R. 7567 - Farm, Food, and National Security Act of 2026 and in discussion draft, the Agricultural Act of 2026 (Farm Bill 2.0).
Issues related to permitting reform.
Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to insurance regulation.
Issues related to data privacy; Issues related to H.R. 8398 - Guidelines for Use, Access, and Responsible Disclosure of Financial Data Act; Issues related to H.R. 8413 - SECURE Data Act; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to coverage of opioid alternatives.
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENVIRONMENTAL DEFENSE ACTION FUND via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to climate change and carbon pricing; Issues related to environmental regulations.
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECRETARY OF STATE, STATE OF DELAWARE via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to corporate governance; Issues related to port funding.
Issues related to the implementation of the Infrastructure Investment and Jobs Act (PL 117-58); Issues related to the PIDP grant process; Issues related to port funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to tariff policy and supply chain policy.
GRID UNITED LLC via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to electricity transmission and permitting reform.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
General immigration issues; Issues related to the Secure America Act (P.L. 119-98); Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to Temporary Protected Status (TPS), including ongoing federal and legal developments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEMOCRATIC MAJORITY FOR ISRAEL via TIBER CREEK GROUP
2026 · second_quarter · Q2
Issues related to U.S.-Israel relations; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 8595 - National Security, Department of State, and Related Programs Appropriations Act, 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL GOVERNORS ASSOCIATION via TIBER CREEK GROUP
2026 · second_quarter · RR
Issues related to state rights, SNAP, reconciliation, cost share shifts to states, surface transportation, and immigration.
Issues related to state rights, SNAP, reconciliation, cost share shifts to states, surface transportation, and immigration.
Issues related to state rights, SNAP, reconciliation, cost share shifts to states, surface transportation, and immigration.
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Issues related to tariff policy and supply chain policy.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
GRID UNITED LLC via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to electricity transmission and permitting reform.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
General immigration issues; Issues related to H.R. 4393 - DIGNIDAD (Dignity) Act of 2025; Issues related to S. 3348 - Dream Act of 2025; Issues related to H.R. 8013 - Keep Innovators in America Act; Issues related to H.R. 7147 - Further Additional Continuing Appropriations Act, 2026; Issues related to Temporary Protected Status (TPS).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEMOCRATIC MAJORITY FOR ISRAEL via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to U.S.-Israel relations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the Medicare Advantage and Medicaid programs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to data privacy; Issues related to artificial intelligence; Issues related to Basel III Endgame capital requirements.
Issues related to insurance regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act.
Issues related to coverage of opioid alternatives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SECRETARY OF STATE, STATE OF DELAWARE via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the implementation of the Infrastructure Investment and Jobs Act (PL 117-58); Issues related to the PIDP grant process; Issues related to port funding; Issues related to bus rapid transit.
Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to corporate governance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENVIRONMENTAL DEFENSE ACTION FUND via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to climate change and carbon pricing; Issues related to environmental regulations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
ENTERGY SERVICES LLC via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to federal permitting reform; Issues related to electricity transmission; Issues related to the implementation of the ADVANCE Act (PL 118-67); Issues related to NRC nominations.
Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to the National Defense Authorization Act for Fiscal Year 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to rare disease treatments, including rare disease research incentives; Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to drug pricing reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CARBON REMOVAL ALLIANCE via TIBER CREEK GROUP
2026 · first_quarter · 1T
Issues related to permanently removing carbon from the atmosphere.
Issues related to funding for clean energy programs; Issues related to the Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (PL 119-74).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EOS ENERGY ENTERPRISES LLC (FKA EOS ENERGY STORAGE LLC) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to energy storage; Issues related to the Section 48 Investment Tax Credit (ITC); Issues related to domestic content and advanced manufacturing; Issues related to the DOE LPO program.
Issues related to installation readiness.
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to energy storage; Issues related to the Section 48 Investment Tax Credit (ITC); Issues related to domestic content and advanced manufacturing; Issues related to the DOE LPO program; Issues related to the One Big Beautiful Bill Act (PL 119-21).
2026 · first_quarter · Q1
Issues related to life insurance.
Issues related to retirement security; Information Reporting of Certain Life Insurance Contract Transactions and Modifications to the Transfer for Valuable Consideration Rules (REG-103083-18).
Issues related to H.R. 20/S. 852 - Richard L. Trumka Protecting the Right to Organize Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025; Issues related to FDA guidance on Alcohol Use Disorder (AUD).
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
GEORGIALINK PUBLIC AFFAIRS GROUP, LLC (O.B.O. DOUGHERTY COUNTY, GA) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to general appropriations; Issues related to federal grant opportunities; General state and local issues.
Issues related to general appropriations; Issues related to federal grant opportunities; General state and local issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF GENENTECH, INC.) via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to clinical trial diversity.
Issues related to Medicare Part B Pricing Reform; Issues relating to Medicaid Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to Plasma-Derived Therapies; Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to National Priority Voucher (CNPV) program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Issues related to intellectual property protections; Issues related to tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to vaccine policy.
Issues related to intellectual property protections.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to reproductive healthcare and IVF.
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to implementation of USC 48(c)(1)(E) - Qualified fuel cell property.
Issues related to the deployment of fuel cells, electrolyzers, hydrogen, and carbon capture; Issues related to onsite power generation and grid stability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to the 340B Program - Public Health Service Act (PL 78-410).
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TIBER CREEK GROUP
2026 · first_quarter · Q1
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability.
Issues related to the 340B Program - Public Health Service Act (PL 78-410).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEMOCRATIC MAJORITY FOR ISRAEL via TIBER CREEK GROUP
2026 · first_quarter · RR
Issues related to the U.S.-Israel relationship and Middle East policy.
INCYTE CORPORATION via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO, INC. via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Issues related to reproductive healthcare and IVF.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO., INC via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to intellectual property protections.
Issues related to vaccine policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Pricing Reform.
Issues related to intellectual property protections; Issues related to Tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLOOM ENERGY via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to implementation of USC 48(c)(1)(E) - Qualified fuel cell property.
Issues related to the deployment of fuel cells, electrolyzers, hydrogen, and carbon capture; Issues related to onsite power generation and grid stability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to Plasma-Derived Therapies; Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to National Priority Voucher (CNPV) program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to the 340B Program - Public Health Service Act (P.L. 78-410).
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF GENENTECH, INC.) via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare Part B Pricing Reform; Issues relating to Medicaid Pricing Reform.
Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to clinical trial diversity.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability.
Issues related to the 340B Program - Public Health Service Act (P.L. 78-410).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) via TIBER CREEK GROUP
2025 · fourth_quarter · Q4
Issues related to tariff policy and supply chain policy.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to state rights, SNAP, reconciliation, cost share shifts to states, surface transportation, and immigration.
Issues related to state rights, SNAP, reconciliation, cost share shifts to states, surface transportation, and immigration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office
Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE